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CASE-LETTER
Toxoplasma gondii Pneumonia in an
Immunocompetent Individual
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Med Sci 2015;350(1):70–71.]
T oxoplasmosis occurs worldwide and is observed in peopleof all ages, especially in those with poor health conditions.
Almost all mammals and birds, especially cats, pigs and dogs,
are naturally infected and spread the disease, and therefore,
frequent contact with these animals, especially consumption
of undercooked animal meat and drinking unclean water, causes
infection.1 Toxoplasmosis pneumonia is the inﬂammation of the
lungs caused by Toxoplasma gondii; it is a latent infection
caused by invasion of the human body by pathogens, and the
symptoms vary. T gondii mainly affects the eyes, brain, heart,
liver, lymph nodes and other organs but rarely affects the lungs.
The prevalence and spectrum of human immunodeﬁciency
virus (HIV)–related opportunistic infections, for example, cere-
bral toxoplasmosis, is 3.5%.2 Although the incidence of T gon-
dii is rarely impacted by the immune response of a normal
individual, the authors encountered 1 patient in the Respiratory
Department of Shanghai Tenth People’s Hospital.
A 59-year-old woman presented at the outpatient depart-
ment of Shanghai Pulmonary Hospital with dry cough, fever
and high body temperature of 37.5°C, which persisted for 10
days before returning to normal. However, the patient com-
plained of chest tightness, which gradually increased, and the
physical examination did not reveal any positive signs. Routine
blood analysis on March 15, 2011, revealed C-reactive proteins
of 5.4 mg/L, white blood cell count of 8.0 3 109 cells per liter,
69.3% neutrophils and 0.4% eosinophils. The PPD skin test was
negative. The patient also tested negative for the HIV-1 anti-
body using Western blot, and therefore, HIV-related opportu-
nistic infections were eliminated. She was not on any
immunosuppressant drugs. Shanghai Pulmonary Hospital chest
computed tomography (CT) examination revealed scattered
patchy areas in both the lungs and ﬂocculent high-density
shadows; the borders were not uniform. Percutaneous lung
biopsy at the CT location revealed a small amount of ﬁbrous
tissue and alveoli. Toxoplasma pneumonia was suspected, and
the blood samples collected from the patient were sent to
Shanghai Institute of Parasitic Diseases for examination and
the samples tested positive for toxoplasma immunoglobulin G
(IgG) antibodies, and the antibody titer is 1:600 (modiﬁed
agglutination test). Based on these results, the patient was ini-
tially diagnosed with toxoplasma pneumonia. She was then
administered 2 sulfamethoxazole compound tablets (sulfame-
thoxazole, 0.4 g and trimethoprim, 80 mg), twice a day orally.
Two weeks later, the patient’s shortness of breath improved,
and she stopped taking the drugs without the consent of the
doctor. However, recurrence of similar symptoms was observed
in July 2011, and the patient presented at Shanghai Tenth Peo-
ple’s Hospital. Physical examination revealed no positive signs.
Routine blood analysis on July 11, 2011, revealed C-reactive
proteins of 4.4 mg/L, white blood cell count of 6.0 3 109 cells
per liter, 64.5% neutrophils and 0.5% eosinophils. A (puriﬁed
protein derivative) PPD skin test was negative. The patient also
tested negative for HIV-1 antibodies using Western blot. The
chest x-ray on July 11, 2011, showed the inﬂammation change
in lower left lung (Figure 1A). A CT examination on July 11,
2011, revealed multiple divergent exudative lesions in the
right, middle and lower lobes of the lungs, and the divergent
exudative lesions resembled clumps of cotton balls. Some
patchy shadows were also observed (Figure 1B). Percutaneous
lung biopsy at the CT location revealed occasional occurrence
of T gondii eggs. Therefore, toxoplasma pneumonia was the
primary diagnosis, and 2 sulfamethoxazole compound tablets
(sulfamethoxazole, 0.4 g and trimethoprim, 80 mg) were
administered twice a day orally along with an intravenous
clindamycin phosphate injection, 0.6 g twice a day. After
a week, the patient’s symptoms improved, and the patient
was discharged from the hospital. Treatment with oral sulfa-
methoxazole tablets continued according to the results of the
chest CT. On July 25, 2011, the chest CT revealed multiple
inﬂammatory lesions in both the lungs and a shadow that
showed obvious absorption. In 4 months, her chest CT was
reviewed 4 times, and on the last CT, that is, on November 28,
2011, each lesion was obviously absorbed. In the ligule left
FIGURE 1. A, The chest x-ray
on July 11, 2011, showed the
inflammation change in lower
left lung. B, A CT examination
on July 11, 2011, revealed mul-
tiple divergent exudative lesions
in the right, middle and lower
lobes of the lungs, and the
divergent exudative lesions
resembled clumps of cotton
balls. Some patchy shadows
were also observed. C, On the
last CT, that is, November 28,
2011, each lesion was obviously
absorbed. In the ligule left lung
segment and lower lobe in both
lungs, the patchy inflammation
showed some change.
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lung segment and lower lobe in both lungs, the patchy inﬂam-
mation showed some change (Figure 1C). Because the patient
did not complain of headache, muscle pain, eye pain or lymph
node enlargement, no other examination was performed.
Two cases of such patients have been reported.3,4 The
patient had not come into contact with any cats, dogs, pigs or
other mammals, was not on immunosuppressants, had no his-
tory of immunosuppressive diseases and her living environment
was healthy; although she was diagnosed with T gondii infec-
tion, the mechanism of which requires further study. The clin-
ical manifestations of the toxoplasmosis complex, often due to
injury of different organs, are varied. The patient may suffer
from fever, rashes, muscle and joint pain, swollen lymph nodes,
meningoencephalitis, eye damage and hepatitis. Most patients
with acute onset experience headaches, muscle pain, dry cough
and other symptoms, whereas other patients cough mucus
bloody sputum, which are symptoms similar to those of upper
respiratory tract infection. During the chronic phase, cough and
expectoration are observed along with wheezing.5 The symp-
toms exhibited by the patient were similar to the clinical man-
ifestations observed in a patient with toxoplasma pneumonia.
Infection with T gondii activates the mononuclear phago-
cytic system and plays a role in phagocytosis. The immune
system of an immunocompetent host then generates an immune
response, and the infection is controlled.6 In immunodeﬁcient
individuals, the tachyzoites may continue to replicate.3,7 Most
individuals are carriers of T gondii and have developed inbuilt
resistance to the infection. Infection with toxoplasma for the
ﬁrst time can be serious and even life-threatening. Therefore,
prevention of toxoplasma infection is critical. The following
methods should be followed to prevent T gondii infection:
effective management of the hair and feces of animal, no con-
sumption of raw and undercooked meat, separation of raw and
cooked food and ingrain the habit of washing hands before
eating and after defecation. Some ﬁsh also carry toxoplasma.
During menstruation, women should ensure effective manage-
ment of menstrual health, and in case of skin abrasions, the
wound should be cleaned properly. No speciﬁc factors have
been described during T gondii lung involvement in immuno-
competent groups. The authors hypothesize that the patient
acquired the infection through inhalation due to high toxicity
of T gondii.
The following observations were made after the diagnosis
and treatment of the patient with toxoplasma pneumonia: (1) Raw
or undercooked meat consumption, contact with infected animals
and potential exposure should be investigated. (2) Toxoplasma
immunological detection and pathology examination with a high
diagnostic value for the diagnosis of toxoplasmosis, the speciﬁc
imaging manifestations such as patchy and ﬂocculent high-density
shadows or the ground-glass opacity, have high reference value
for diagnosing. (3) Once toxoplasma pneumonia is diagnosed,
antibiotic therapy should be administered, such as macrolide or
sulfonamide antibiotics, whereas acetylspiramycin is administered
to pregnant women.
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